dapsone has been researched along with Glucosephosphate Dehydrogenase Deficiency in 41 studies
Glucosephosphate Dehydrogenase Deficiency: A disease-producing enzyme deficiency subject to many variants, some of which cause a deficiency of GLUCOSE-6-PHOSPHATE DEHYDROGENASE activity in erythrocytes, leading to hemolytic anemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chlorproguanil-dapsone (CD) has been linked to hemolysis in symptomatic glucose-6-phosphate dehydrogenase deficient (G6PDd) children." | 9.20 | Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants. ( Alifrangis, M; Baraka, V; Carneiro, I; Chandramohan, D; Gesase, S; Gosling, R; Hashim, R; Ishengoma, D; Mosha, J; Poirot, E; Vittinghoff, E, 2015) |
| "The appearance of bite cells associated with methemoglobinemia can be caused by oxidizing drugs such as dapsone in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or high drug serum levels." | 8.12 | Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria. ( Awan, M; Brown, LE; Gandelman, JS; Geere, M; Hu, Y; Kogan, SC; Leavitt, AD; Pearson, HJ, 2022) |
| "Haemolysis and frank anaemia from dapsone therapy of leprosy has been long recognized." | 7.68 | Effect of dapsone on haemoglobin concentration in patients with leprosy. ( Byrd, SR; Gelber, RH, 1991) |
| "Malaria is a leading cause of mortality, particularly in sub-Saharan African children." | 6.77 | Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria. ( Bassat, Q; D' Alessandro, U; Daniel, A; Forret, P; González, R; Machevo, S; Nabasumba, C; Piola, P; Robert, A; Talisuna, A; Turyakira, E; Van Geertruyden, JP; van Loen, H; Van Malderen, C; Van Overmeir, C; Yeka, A, 2012) |
| "Dapsone is a highly useful drug for treating a variety of pathologies but oral dapsone is contraindicated in patients with G6PDd due to oxidative stress-induced anemia." | 5.91 | Hemolysis and Metabolic Lesion of G6PD Deficient RBCs in Response to Dapsone Hydroxylamine in a Humanized Mouse Model. ( D'Alessandro, A; Dziewulska, KH; Hay, AM; Reisz, JA; Zimring, JC, 2023) |
| "Oxidant hemolysis is a known complication of dapsone, but its frequency in adult patients who have undergone a SCT for hematological malignancies is not well established." | 5.38 | High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency. ( Bredeson, C; George, B; Hari, PN; Harrington, AM; Kroft, SH; Olteanu, H, 2012) |
| "Chlorproguanil-dapsone (CD) has been linked to hemolysis in symptomatic glucose-6-phosphate dehydrogenase deficient (G6PDd) children." | 5.20 | Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants. ( Alifrangis, M; Baraka, V; Carneiro, I; Chandramohan, D; Gesase, S; Gosling, R; Hashim, R; Ishengoma, D; Mosha, J; Poirot, E; Vittinghoff, E, 2015) |
| "The appearance of bite cells associated with methemoglobinemia can be caused by oxidizing drugs such as dapsone in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or high drug serum levels." | 4.12 | Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria. ( Awan, M; Brown, LE; Gandelman, JS; Geere, M; Hu, Y; Kogan, SC; Leavitt, AD; Pearson, HJ, 2022) |
| "Haemolysis and frank anaemia from dapsone therapy of leprosy has been long recognized." | 3.68 | Effect of dapsone on haemoglobin concentration in patients with leprosy. ( Byrd, SR; Gelber, RH, 1991) |
| "Malaria is a leading cause of mortality, particularly in sub-Saharan African children." | 2.77 | Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria. ( Bassat, Q; D' Alessandro, U; Daniel, A; Forret, P; González, R; Machevo, S; Nabasumba, C; Piola, P; Robert, A; Talisuna, A; Turyakira, E; Van Geertruyden, JP; van Loen, H; Van Malderen, C; Van Overmeir, C; Yeka, A, 2012) |
| "G6PD deficiency is common in African patients with malaria and until a reliable and simple G6PD test is available, the use of 8-aminoquinolines will remain problematic." | 2.76 | Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. ( Carter, N; Duparc, S; Pamba, A; Waitumbi, JN, 2011) |
| "falciparum malaria was evaluated according to G6PD deficiency in a secondary analysis of an open-label, randomized clinical trial." | 2.73 | High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency. ( Avellino, P; Bancone, G; d'Alessandro, U; Fanello, CI; Karema, C; Lee, SJ; Modiano, D; Uwimana, A, 2008) |
| "Panniculitis is a recognized, but rare complication of α1-antitrypsin (A1AT) deficiency." | 2.50 | Alpha-1-antitrypsin deficiency-associated panniculitis: a case report. ( Cardoso, J; Carvalho, R; Chaveiro, A; Laureano, A, 2014) |
| "Dapsone is a highly useful drug for treating a variety of pathologies but oral dapsone is contraindicated in patients with G6PDd due to oxidative stress-induced anemia." | 1.91 | Hemolysis and Metabolic Lesion of G6PD Deficient RBCs in Response to Dapsone Hydroxylamine in a Humanized Mouse Model. ( D'Alessandro, A; Dziewulska, KH; Hay, AM; Reisz, JA; Zimring, JC, 2023) |
| "Oxidant hemolysis is a known complication of dapsone, but its frequency in adult patients who have undergone a SCT for hematological malignancies is not well established." | 1.38 | High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency. ( Bredeson, C; George, B; Hari, PN; Harrington, AM; Kroft, SH; Olteanu, H, 2012) |
| " Drug-induced acute hemolytic anemia in G6PD A- subjects can be life-threatening, depending on the nature and dosage of the drug trigger." | 1.38 | Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. ( Carter, N; Duparc, S; Luzzatto, L; Pamba, A; Premji, Z; Richardson, ND; Tiono, AB, 2012) |
| "Here we determined the prevalence of G6PD deficiency and the occurrence of G6PD-related hemolytic events in a large cohort of patients." | 1.36 | Prevalence of G6PD deficiency in a large cohort of HIV-infected patients. ( Giordano, TP; Serpa, JA; Villarreal-Williams, E, 2010) |
| "Dapsone was the most common etiology of acquired methemoglobinemia, accounting for 42% of all cases." | 1.32 | Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. ( Ash-Bernal, R; Wise, R; Wright, SM, 2004) |
| "Twenty-one cases of agranulocytosis following dosage with one tablet of Maloprim given once or twice weekly are reviewed." | 1.27 | Agranulocytosis associated with maloprim: review of cases. ( Farquhar, JA; Hutchinson, DB; Whiteman, PD, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (46.34) | 18.7374 |
| 1990's | 5 (12.20) | 18.2507 |
| 2000's | 2 (4.88) | 29.6817 |
| 2010's | 13 (31.71) | 24.3611 |
| 2020's | 2 (4.88) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y | 3 |
| Geere, M | 3 |
| Awan, M | 3 |
| Leavitt, AD | 3 |
| Brown, LE | 3 |
| Pearson, HJ | 3 |
| Gandelman, JS | 3 |
| Kogan, SC | 3 |
| Dziewulska, KH | 1 |
| Reisz, JA | 1 |
| Hay, AM | 1 |
| D'Alessandro, A | 1 |
| Zimring, JC | 1 |
| Rochford, R | 1 |
| Ohrt, C | 1 |
| Baresel, PC | 1 |
| Campo, B | 1 |
| Sampath, A | 1 |
| Magill, AJ | 1 |
| Tekwani, BL | 1 |
| Walker, LA | 1 |
| Luzzatto, L | 3 |
| Seneca, E | 1 |
| Laureano, A | 1 |
| Carvalho, R | 1 |
| Chaveiro, A | 1 |
| Cardoso, J | 1 |
| Poirot, E | 1 |
| Vittinghoff, E | 1 |
| Ishengoma, D | 1 |
| Alifrangis, M | 1 |
| Carneiro, I | 1 |
| Hashim, R | 1 |
| Baraka, V | 1 |
| Mosha, J | 1 |
| Gesase, S | 1 |
| Chandramohan, D | 1 |
| Gosling, R | 1 |
| Schulkes, KJ | 1 |
| Tervaert, JW | 1 |
| Rijken, F | 1 |
| Haas, LE | 1 |
| Fanello, CI | 1 |
| Karema, C | 1 |
| Avellino, P | 1 |
| Bancone, G | 1 |
| Uwimana, A | 1 |
| Lee, SJ | 1 |
| d'Alessandro, U | 1 |
| Modiano, D | 1 |
| Serpa, JA | 1 |
| Villarreal-Williams, E | 1 |
| Giordano, TP | 1 |
| Olteanu, H | 1 |
| Harrington, AM | 1 |
| George, B | 1 |
| Hari, PN | 1 |
| Bredeson, C | 1 |
| Kroft, SH | 1 |
| Carter, N | 2 |
| Pamba, A | 2 |
| Duparc, S | 2 |
| Waitumbi, JN | 1 |
| Van Malderen, C | 1 |
| Van Geertruyden, JP | 1 |
| Machevo, S | 1 |
| González, R | 1 |
| Bassat, Q | 1 |
| Talisuna, A | 1 |
| Yeka, A | 1 |
| Nabasumba, C | 1 |
| Piola, P | 1 |
| Daniel, A | 1 |
| Turyakira, E | 1 |
| Forret, P | 1 |
| Van Overmeir, C | 1 |
| van Loen, H | 1 |
| Robert, A | 1 |
| D' Alessandro, U | 1 |
| Stichtenoth, D | 1 |
| Greenfield, NP | 1 |
| Maibach, H | 1 |
| Richardson, ND | 1 |
| Premji, Z | 1 |
| Tiono, AB | 1 |
| Ash-Bernal, R | 1 |
| Wise, R | 1 |
| Wright, SM | 1 |
| Bernstein, JE | 1 |
| Lorincz, AL | 1 |
| Pettit, JH | 1 |
| Magon, AM | 1 |
| Leipzig, RM | 2 |
| Zannoni, VG | 1 |
| Brewer, GJ | 2 |
| Magon, A | 1 |
| Bloom, K | 1 |
| Ponnampalam, JT | 1 |
| Todd, P | 1 |
| Samaratunga, IR | 1 |
| Pembroke, A | 1 |
| Mysore, V | 1 |
| al-Suwaid, AR | 1 |
| Poshyachinda, M | 1 |
| Buachum, V | 1 |
| Mahasandana, S | 1 |
| Shanks, GD | 1 |
| Edstein, MD | 1 |
| Suriyamongkol, V | 1 |
| Timsaad, S | 1 |
| Webster, HK | 1 |
| Byrd, SR | 1 |
| Gelber, RH | 1 |
| Hutchinson, DB | 1 |
| Whiteman, PD | 1 |
| Farquhar, JA | 1 |
| Carson, PE | 4 |
| Cucinell, SA | 1 |
| Rebert, C | 1 |
| Clyde, D | 1 |
| Willerson, D | 1 |
| Rieckmann, KH | 1 |
| Kass, L | 1 |
| Frischer, H | 1 |
| Bowman, JE | 1 |
| Khaire, DS | 1 |
| Magar, NG | 1 |
| Glader, BE | 1 |
| Conrad, ME | 1 |
| Scott, GL | 1 |
| Rasbridge, MR | 1 |
| Onadeko, BO | 1 |
| Bademosi, O | 1 |
| McNamara, JV | 1 |
| Eppes, RB | 2 |
| Powell, RD | 2 |
| Degowin, RL | 1 |
| Gaetani, G | 1 |
| Salvidio, E | 1 |
| Pannacciulli, I | 1 |
| Ajmar, F | 1 |
| Paravidino, G | 1 |
| Raper, AB | 1 |
| Lewis, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Study on the Tolerability and Efficacy of the Combination Chlorproguanil-Dapsone+Artesunate Compared to Amodiaquine+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria in Rwandan Children[NCT00461578] | 800 participants | Interventional | 2005-04-30 | Completed | |||
| A Multi-centre, Randomised, Double-blind, Double Dummy Study Comparing the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Artemether-lumefantrine in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children and Adoles[NCT00344006] | Phase 3 | 1,395 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Multi-centre, Randomised, Double-blind Study to Compare the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Chlorproguanil-dapsone in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children, Adolescents and Adults [NCT00371735] | Phase 3 | 900 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial[NCT05131295] | Phase 3 | 49 participants (Actual) | Interventional | 2007-09-05 | Completed | ||
| Intravenous Lidocaine Infusion in the Management of Post-operative Pain in Colorectal Patients[NCT01836614] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2015-01-31 | Withdrawn (stopped due to Study was closed due to recommendations of performing a PK study first.) | ||
| Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Prilocaine Versus Lidocaine[NCT01402869] | 91 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in percentage of methemoglobin in blood from baseline level to peak level (NCT01402869)
Timeframe: From administration of local anesthetic or start of restorative procedures to time at which maximum methemoglobin blood level was documented during dental treatment for an average of 2 hours
| Intervention | percentage of methemoglobin in blood (Mean) |
|---|---|
| Prilocaine | 2.73 |
| Lidocaine | 0.78 |
| No Local Anesthetic | 0.76 |
The maximum percentage of methemoglobin in blood (NCT01402869)
Timeframe: Measured at 10 second intervals during dental treatment for an average of 2 hours
| Intervention | percentage of methemoglobin in blood (Mean) |
|---|---|
| Prilocaine | 3.55 |
| Lidocaine | 1.63 |
| No Local Anesthetic | 1.60 |
The length of time between the administration of local anesthetic (Prilocaine and Lidocaine Groups) or start of restorative dental procedures (No local anesthetic Group) and the time at which the maximum methemoglobin blood level is observed. (NCT01402869)
Timeframe: Measured at 10 second intervals during dental treatment for an average of 2 hours
| Intervention | minutes (Mean) |
|---|---|
| Prilocaine | 62.73 |
| Lidocaine | 57.50 |
| No Local Anesthetic | 29.50 |
3 reviews available for dapsone and Glucosephosphate Dehydrogenase Deficiency
| Article | Year |
|---|---|
G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications.
Topics: Anemia, Hemolytic; Animals; Antimalarials; Dapsone; Female; Glucosephosphate Dehydrogenase Deficienc | 2014 |
Alpha-1-antitrypsin deficiency-associated panniculitis: a case report.
Topics: alpha 1-Antitrypsin Deficiency; Biopsy; Colchicine; Contraindications; Dapsone; Erythema; Female; Gl | 2014 |
Sulfonamides and sulfones in dermatologic therapy.
Topics: Animals; Chancroid; Conjunctivitis, Inclusion; Dapsone; Dermatitis Herpetiformis; Erythrocytes; Gluc | 1981 |
6 trials available for dapsone and Glucosephosphate Dehydrogenase Deficiency
| Article | Year |
|---|---|
Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants.
Topics: Antimalarials; Cohort Studies; Dapsone; Double-Blind Method; Drug Combinations; Female; Genotype; Gl | 2015 |
High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dapsone; Drug Combina | 2008 |
Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials.
Topics: Adolescent; Africa; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dapsone; Drug | 2011 |
Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials.
Topics: Adolescent; Africa; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dapsone; Drug | 2011 |
Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials.
Topics: Adolescent; Africa; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dapsone; Drug | 2011 |
Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials.
Topics: Adolescent; Africa; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dapsone; Drug | 2011 |
Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria.
Topics: Africa South of the Sahara; Anemia, Hemolytic; Antimalarials; Artemisinins; Artesunate; Case-Control | 2012 |
Efficacy of WHO regimens in the management of leprosy patients with G6PD deficiency.
Topics: Adolescent; Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Glucosephosphate Dehydro | 1999 |
Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border.
Topics: Blood Cells; Cambodia; Dapsone; Doxycycline; Drug Therapy, Combination; Drug Tolerance; Glucosephosp | 1992 |
32 other studies available for dapsone and Glucosephosphate Dehydrogenase Deficiency
| Article | Year |
|---|---|
Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria.
Topics: Dapsone; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Methemoglobinemia; Ur | 2022 |
Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria.
Topics: Dapsone; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Methemoglobinemia; Ur | 2022 |
Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria.
Topics: Dapsone; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Methemoglobinemia; Ur | 2022 |
Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria.
Topics: Dapsone; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Methemoglobinemia; Ur | 2022 |
Hemolysis and Metabolic Lesion of G6PD Deficient RBCs in Response to Dapsone Hydroxylamine in a Humanized Mouse Model.
Topics: Animals; Dapsone; Erythrocytes; Glucose; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Human | 2023 |
Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity.
Topics: Aminoquinolines; Anemia, Hemolytic; Animals; Antimalarials; Chloroquine; Combined Modality Therapy; | 2013 |
Dapsone hypersensitivity syndrome not related to G6PD deficiency.
Topics: Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Dapsone; Diagnosis, Differential; Dru | 2015 |
The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics.
Topics: Anemia, Hemolytic; Antimalarials; Dapsone; Drug Combinations; Drug Resistance; Glucosephosphate Dehy | 2010 |
Prevalence of G6PD deficiency in a large cohort of HIV-infected patients.
Topics: Adult; Aged; Anemia, Hemolytic; Anti-Infective Agents; Black or African American; Cohort Studies; Da | 2010 |
High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency.
Topics: Adult; Anti-Infective Agents; Dapsone; Female; Glucosephosphate Dehydrogenase; Glucosephosphate Dehy | 2012 |
[Lip cyanosis in dapsone therapy: should the dosage be reduced?].
Topics: Cyanosis; Dapsone; Dose-Response Relationship, Drug; Female; Folic Acid Antagonists; Glucosephosphat | 2012 |
Pharmacogenomic biomarkers in dermatologic drugs.
Topics: Androstenes; Aryl Hydrocarbon Hydroxylases; Biomarkers; Chloroquine; Cytochrome P-450 CYP2C19; Cytoc | 2013 |
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone.
Topics: Acute Disease; Adolescent; Africa; Anemia, Hemolytic; Antimalarials; Blood Transfusion; Child; Child | 2012 |
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone.
Topics: Acute Disease; Adolescent; Africa; Anemia, Hemolytic; Antimalarials; Blood Transfusion; Child; Child | 2012 |
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone.
Topics: Acute Disease; Adolescent; Africa; Anemia, Hemolytic; Antimalarials; Blood Transfusion; Child; Child | 2012 |
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone.
Topics: Acute Disease; Adolescent; Africa; Anemia, Hemolytic; Antimalarials; Blood Transfusion; Child; Child | 2012 |
Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Chi | 2004 |
Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Chi | 2004 |
Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Chi | 2004 |
Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Chi | 2004 |
Is dapsone safe?
Topics: Anemia, Hemolytic; Dapsone; Glucosephosphate Dehydrogenase Deficiency; Humans; Leprosy | 1981 |
Interactions of glucose-6-phosphate dehydrogenase deficiency with drug acetylation and hydroxylation reactions.
Topics: Acetylation; Animals; Dapsone; Erythrocytes; Glucosephosphate Dehydrogenase Deficiency; Glutathione; | 1981 |
Pharmacogenetic interactions in G6PD deficiency and development of an in vitro test to predict a drug's hemolytic potential.
Topics: Animals; Dapsone; Drug Evaluation, Preclinical; Erythrocytes; Glucosephosphate Dehydrogenase Deficie | 1981 |
Haemoglobinuria after a single dose treatment with dapsone and pyrimethamine for falciparum malaria in a patient with glucose-6-phosphate dehydrogenase deficiency.
Topics: Child, Preschool; Dapsone; Drug Combinations; Glucosephosphate Dehydrogenase; Glucosephosphate Dehyd | 1981 |
Screening for glucose-6-phosphate dehydrogenase deficiency prior to dapsone therapy.
Topics: Adolescent; Anemia, Hemolytic; Contraindications; Dapsone; Female; Glucosephosphate Dehydrogenase De | 1994 |
Haemolytic side effects of DFD in normal and G-6-PD deficient Thais.
Topics: Adult; Dapsone; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Middle Aged; Thailand | 1978 |
Glucose-6-phosphate dehydrogenase deficiency.
Topics: Acetaminophen; Dapsone; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans | 1991 |
Effect of dapsone on haemoglobin concentration in patients with leprosy.
Topics: Adolescent; Adult; Aged; Child; Dapsone; Female; Glucosephosphate Dehydrogenase Deficiency; Hemoglob | 1991 |
Agranulocytosis associated with maloprim: review of cases.
Topics: Adult; Agranulocytosis; Antimalarials; Dapsone; Dose-Response Relationship, Drug; Drug Combinations; | 1986 |
Hemolysis due to inherited erythrocyte enzyme deficiencies.
Topics: Age Factors; Asia, Southeastern; Dapsone; Erythrocytes; Genetics, Population; Glucose; Glucosephosph | 1968 |
Clinical pharmacology of diformyldapsone.
Topics: Chloroquine; Dapsone; Drug Therapy, Combination; Erythrocytes; Formaldehyde; Glucosephosphate Dehydr | 1974 |
The chemoprophylactic use of diformyl diaminodiphenyl sulfone (DFD) in falciparum malaria.
Topics: Adult; Anopheles; Antimalarials; Blood Cell Count; Chloroquine; Dapsone; Drug Resistance, Microbial; | 1972 |
Haemolytic effects of DDS in leprosy patients.
Topics: Adult; Anemia, Hemolytic; Dapsone; Erythrocytes; Female; Glucosephosphate Dehydrogenase Deficiency; | 1972 |
Hemolysis by diphenylsulfones: comparative effects of DDS and hydroxylamine-DDS.
Topics: Amitrole; Animals; Ascorbic Acid; Catalase; Cell Survival; Chromium Isotopes; Dapsone; Erythrocytes; | 1973 |
The in vitro action of dapsone and its derivatives on normal and G6PD-deficient red cells.
Topics: Acetylcholinesterase; Adenosine Triphosphate; Cell Membrane; Dapsone; Erythrocytes; Glucose; Glucose | 1973 |
Glucose-6-phosphate dehydrogenase deficiency and intravascular haemolysis.
Topics: Adolescent; Adult; Anemia, Hemolytic; Aspirin; Dapsone; Female; Glucosephosphate Dehydrogenase Defic | 1974 |
The effects of para-aminobenzoic acid on the hemolytic effects of 4, 4'-diaminodiphenylsulfone.
Topics: Adult; Aminobenzoates; Black or African American; Dapsone; Glucosephosphate Dehydrogenase Deficiency | 1966 |
The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency.
Topics: Adult; Black or African American; Dapsone; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Hum | 1966 |
Absence of hemolytic effects of L-DOPA on transfused G6PD-deficient erythrocytes.
Topics: Blood Transfusion; Chromium Isotopes; Dapsone; Dihydroxyphenylalanine; Erythrocytes; Favism; Female; | 1970 |
A commentary on the anti-sickling effect of the phenothiazine drugs.
Topics: Anemia, Sickle Cell; Child; Dapsone; Erythrocytes; Female; Glucosephosphate Dehydrogenase; Glucoseph | 1968 |
Experience with promazine in sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Dapsone; Female; Glucosephosphate D | 1968 |